NCT05416931

ACD440 Gel in Peripheral Neuropathic Pain

A Phase 2a, Randomized, Double-blind, Placebo-controlled Crossover Study to Explore the Effects of ACD440 in Patients With Peripheral Neuropathic Pain With Sensory Hypersensitivity.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: AlzeCure Pharma · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a double-blind, randomized, placebo-controlled crossover outpatient study in patients with peripheral neuropathic pain with allodynia or hyperalgesia to cold, heat, brush and/ or pinprick stimulation. Patients will in random order receive ACD440 Gel or placebo treatment twice daily for 7 days, topically applied to the painful area. This is followed by a 2-week washout period, then receive the alternate treatment.

Conditions

• Peripheral Neuropathic Pain

Interventions

Type	Name	Description
DRUG	ACD440 Gel 14mg/g	Topical application to painful area
DRUG	Placebo Gel	Topical application to painful area

Timeline

• Start date: 2022-06-20
• Primary completion: 2023-03-10
• Completion: 2023-03-10
• First posted: 2022-06-14
• Last updated: 2023-03-23

Locations

1 site across 1 country: Sweden